The coupling of epidermal growth factor receptor down regulation by 1alpha,25-dihydroxyvitamin D3 to the hormone-induced cell cycle arrest at the G1-S checkpoint in ovarian cancer cells

Molecular and Cellular Endocrinology

Volumn 338, Issue 1-2, 2011, Pages 58-67

  Shen, Zheng ^a   Zhang, Xiaohui ^a   Tang, Jinfu ^a   Kasiappan, Ravi ^a   Jinwal, Umesh ^a   Li, Pengfei ^a   Hann, Shan ^a   Nicosia, Santo V ^a,b   Wu, Jie ^a,b   Zhang, Xiaohong ^a,b   Bai, Wenlong ^a,b  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

Cell cycle; EGF; EGFR; Ovarian cancer; Vitamin D; Vitamin D receptor

Indexed keywords

CALCITRIOL; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN P27; VITAMIN D;

ARTICLE; CANCER CELL; CANCER INHIBITION; CANCER RESISTANCE; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL LEVEL; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; FEMALE; GENE IDENTIFICATION; GENE OVEREXPRESSION; GENE REPRESSION; GENE TARGETING; GENETIC LINKAGE; HORMONAL REGULATION; HUMAN; HUMAN CELL; INTRON; OVARY CANCER; PRIORITY JOURNAL; PROTEIN DNA BINDING; RECEPTOR DOWN REGULATION; REPORTER GENE; TRANSCRIPTION REGULATION; VITAMIN D RESPONSIVE ELEMENT;

CALCITRIOL; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR P27; CYCLINS; DOWN-REGULATION; EPIDERMAL GROWTH FACTOR; FEMALE; G1 PHASE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, REPORTER; HUMANS; INTRONS; LUCIFERASES, FIREFLY; OVARIAN NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; VITAMIN D RESPONSE ELEMENT;

EID: 79955541995     PISSN: 03037207     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mce.2011.02.023     Document Type: Article

References (40)

1. Antonyak M.A., Moscatello D.K., Wong A.J. Constitutive activation of c-Jun N-terminal kinase by a mutant epidermal growth factor receptor. J. Biol. Chem. 1998, 273:2817-2822.
2. Balmanno K., Cook S.J. Sustained MAP kinase activation is required for the expression of cyclin D1, p21Cip1 and a subset of AP-1 proteins in CCL39 cells. Oncogene 1999, 18:3085-3097.
3. Blutt S.E., Polek T.C., Stewart L.V., Kattan M.W., Weigel N.L. A calcitriol analogue EB1089, inhibits the growth of LNCaP tumors in nude mice. Cancer Res. 2000, 60:779-782.
4. Boisseau-Garsaud A.M., Donatien P., Margerin C., Taieb A. EGF receptor expression and growth of psoriatic and normal human keratinocytes are modulated by 1.25 (OH)2-vitamin D3 ex vivo. Arch. Dermatol. Res. 1996, 288:453-457.
5. Buerger H., Gebhardt F., Schmidt H., Beckmann A., Hutmacher K., Simon R., Lelle R., Boecker W., Brandt B. Length and loss of heterozygosity of an intron 1 polymorphic sequence of egfr is related to cytogenetic alterations and epithelial growth factor receptor expression. Cancer Res. 2000, 60:854-857.
6. Busse D., Doughty R.S., Ramsey T.T., Russell W.E., Price J.O., Flanagan W.M., Shawver L.K., Arteaga C.L. Reversible G(1) arrest induced by inhibition of the epidermal growth factor receptor tyrosine kinase requires up-regulation of p27(KIP1) independent of MAPK activity. J. Biol. Chem. 2000, 275:6987-6995.
7. Chrysogelos S.A. Chromatin structure of the EGFR gene suggests a role for intron 1 sequences in its regulation in breast cancer cells. Nucleic Acids Res. 1993, 21:5736-5741.
8. Colston K.W., Mackay A.G., James S.Y., Binderup L., Chander S., Coombes R.C. EB1089: a new vitamin D analogue that inhibits the growth of breast cancer cells in vivo and in vitro. Biochem. Pharmacol. 1992, 44:2273-2280.
9. Cordero J.B., Cozzolino M., Lu Y., Vidal M., Slatopolsky E., Stahl P.D., Barbieri M.A., Dusso A. 1,25-Dihydroxyvitamin D down-regulates cell membrane growth- and nuclear growth-promoting signals by the epidermal growth factor receptor. J. Biol. Chem. 2002, 277:38965-38971.
10. Gebhardt F., Zanker K.S., Brandt B. Modulation of epidermal growth factor receptor gene transcription by a polymorphic dinucleotide repeat in intron 1. J. Biol. Chem. 1999, 274:13176-13180.
11. Gonzalez E.A., Disthabanchong S., Kowalewski R., Martin K.J. Mechanisms of the regulation of EGF receptor gene expression by calcitriol and parathyroid hormone in UMR 106-01 cells. Kidney Int. 2002, 61:1627-1634.
12. Haley J.D., Waterfield M.D. Contributory effects of de novo transcription and premature transcript termination in the regulation of human epidermal growth factor receptor proto-oncogene RNA synthesis. J. Biol. Chem. 1991, 266:1746-1753.
13. Jiang F., Bao J., Li P., Nicosia S.V., Bai W. Induction of ovarian cancer cell apoptosis by 1,25-dihydroxyvitamin D3 through the down-regulation of telomerase. J. Biol. Chem. 2004, 279:53213-53221.
14. Jiang F., Li P., Fornace A.J., Nicosia S.V., Bai W. G2/M arrest by 1,25-dihydroxyvitamin D3 in ovarian cancer cells mediated through the induction of GADD45 via an exonic enhancer. J. Biol. Chem. 2003, 278:48030-48040.
15. Koga M., Eisman J.A., Sutherland R.L. Regulation of epidermal growth factor receptor levels by 1,25-dihydroxyvitamin D3 in human breast cancer cells. Cancer Res. 1988, 48:2734-2739.
16. Lassus H., Sihto H., Leminen A., Joensuu H., Isola J., Nupponen N.N., Butzow R. Gene amplification, mutation, and protein expression of EGFR and mutations of ERBB2 in serous ovarian carcinoma. J. Mol. Med. 2006, 84:671-681.
17. Lee H., Jiang F., Wang Q., Nicosia S.V., Yang J., Su B., Bai W. MEKK1 activation of human estrogen receptor alpha and stimulation of the agonistic activity of 4-hydroxytamoxifen in endometrial and ovarian cancer cells. Mol. Endocrinol. 2000, 14:1882-1896.
18. Li P., Li C., Zhao X., Zhang X., Nicosia S.V., Bai W. p27(Kip1) stabilization and G(1) arrest by 1,25-dihydroxyvitamin D(3) in ovarian cancer cells mediated through down regulation of cyclin E/CDK2 kinase and SCF/Skp2 ubiquitin ligase. J. Biol. Chem. 2004, 279:25260-25267.
19. Lin S.Y., Makino K., Xia W., Matin A., Wen Y., Kwong K.Y., Bourguignon L., Hung M.C. Nuclear localization of EGF receptor and its potential new role as a transcription factor. Nat. Cell. Biol. 2001, 3:802-808.
20. Maekawa T., Imamoto F., Merlino G.T., Pastan I., Ishii S. Cooperative function of two separate enhancers of the human epidermal growth factor receptor proto-oncogene. J. Biol. Chem. 1989, 264:5488-5494.
21. Maihle N.J., Baron A.T., Barrette B.A., Boardman C.H., Christensen T.A., Cora E.M., Faupel-Badger J.M., Greenwood T., Juneja S.C., Lafky J.M., et al. EGF/ErbB receptor family in ovarian cancer. Cancer Treat. Res. 2002, 107:247-258.
22. Malloy P.J., Feldman D. Inactivation of the human vitamin D receptor by caspase-3. Endocrinology 2009, 150:679-686.
23. McGaffin K.R., Acktinson L.E., Chrysogelos S.A. Growth and EGFR regulation in breast cancer cells by vitamin D and retinoid compounds. Breast Cancer Res. Treat. 2004, 86:55-73.
24. McGaffin K.R., Chrysogelos S.A. Identification and characterization of a response element in the EGFR promoter that mediates transcriptional repression by 1,25-dihydroxyvitamin D3 in breast cancer cells. J. Mol. Endocrinol. 2005, 35:117-133.
25. Miettinen S., Ahonen M.H., Lou Y.R., Manninen T., Tuohimaa P., Syvala H., Ylikomi T. Role of 24-hydroxylase in vitamin D3 growth response of OVCAR-3 ovarian cancer cells. Int. J. Cancer 2004, 108:367-373.
26. Morishige K., Kurachi H., Amemiya K., Fujita Y., Yamamoto T., Miyake A., Tanizawa O. Evidence for the involvement of transforming growth factor alpha and epidermal growth factor receptor autocrine growth mechanism in primary human ovarian cancers in vitro. Cancer Res. 1991, 51:5322-5328.
27. Moscatello D.K., Ramirez G., Wong A.J. A naturally occurring mutant human epidermal growth factor receptor as a target for peptide vaccine immunotherapy of tumors. Cancer Res. 1997, 57:1419-1424.
28. Nakagawa K., Kawaura A., Kato S., Takeda E., Okano T. 1 alpha, 25-Dihydroxyvitamin D(3) is a preventive factor in the metastasis of lung cancer. Carcinogenesis 2005, 26:429-440.
29. Niikura H., Sasano H., Sato S., Yajima A. Expression of epidermal growth factor-related proteins and epidermal growth factor receptor in common epithelial ovarian tumors. Int. J. Gynecol. Pathol. 1997, 16:60-68.
30. Nishikawa R., Ji X.D., Harmon R.C., Lazar C.S., Gill G.N., Cavenee W.K., Huang H.J. A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity. Proc. Natl. Acad. Sci. U.S.A. 1994, 91:7727-7731.
31. Sherr C.J. The Pezcoller lecture: cancer cell cycles revisited. Cancer Res. 2000, 60:3689-3695.
32. Toell A., Polly P., Carlberg C. All natural DR3-type vitamin D response elements show a similar functionality in vitro. Biochem. J. 2000, 2(352 Pt):301-309.
33. Tran S.E., Holmstrom T.H., Ahonen M., Kahari V.M., Eriksson J.E. MAPK/ERK overrides the apoptotic signaling from Fas, TNF, and TRAIL receptors. J. Biol. Chem. 2001, 276:16484-16490.
34. Wong A.J., Ruppert J.M., Bigner S.H., Grzeschik C.H., Humphrey P.A., Bigner D.S., Vogelstein B. Structural alterations of the epidermal growth factor receptor gene in human gliomas. Proc. Natl. Acad. Sci. U.S.A. 1992, 89:2965-2969.
35. Wu X., Rubin M., Fan Z., DeBlasio T., Soos T., Koff A., Mendelsohn J. Involvement of p27KIP1 in G1 arrest mediated by an anti-epidermal growth factor receptor monoclonal antibody. Oncogene 1996, 12:1397-1403.
36. Yanagisawa J., Yanagi Y., Masuhiro Y., Suzawa M., Watanabe M., Kashiwagi K., Toriyabe T., Kawabata M., Miyazono K., Kato S. Convergence of transforming growth factor-beta and vitamin D signaling pathways on SMAD transcriptional coactivators. Science 1999, 283:1317-1321.
37. Yue J., Frey R.S., Mulder K.M. Cross-talk between the Smad1 and Ras/MEK signaling pathways for TGFbeta. Oncogene 1999, 18:2033-2037.
38. Zhang X., Jiang F., Li P., Li C., Ma Q., Nicosia S.V., Bai W. Growth suppression of ovarian cancer xenografts in nude mice by vitamin D analogue EB1089. Clin. Cancer Res. 2005, 11:323-328.
39. Zhang X., Li P., Bao J., Nicosia S.V., Wang H., Enkemann S.A., Bai W. Suppression of death receptor-mediated apoptosis by 1,25-dihydroxyvitamin D3 revealed by microarray analysis. J. Biol. Chem. 2005, 280:35458-35468.
40. Zhang X., Nicosia S.V., Bai W. Vitamin D receptor is a novel drug target for ovarian cancer treatment. Curr. Cancer Drug Targets 2006, 6:229-244.